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Abstract Emerin is a nuclear membrane-anchored protein
which is absent or mutated in patients affected by Emery^
Dreifuss muscular dystrophy. In this study, we induced apoptosis
in cultured mouse myoblasts to evaluate emerin fate during the
nuclear destabilization involved in programmed cell death.
Emerin proteolysis was observed in myocytes during the
apoptotic process. Myoblast apoptosis and emerin degradation
were associated with chromatin compaction and detachment from
the nuclear lamina, as detected by electron microscopy. In vivo
specific inhibition of caspase 3 or caspase 6 activity completely
abolished emerin proteolysis. These results show that the process
of programmed cell death in muscle cells leads to emerin
proteolysis, which appears to be related to caspase 6 activation
and to cleavage of other nuclear envelope proteins, that share
sequence homologies or functional features with emerin. ß 2001
Federation of European Biochemical Societies. Published by
Elsevier Science B.V. All rights reserved.
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1. Introduction
Features of programmed cell death consist of a very partic-
ular nuclear behavior involving chromatin progressive mar-
gination and compaction, frequently appearing as cup-shaped
compact areas [1]. In the following stages, the original nucleus
splits in a number of dense micronuclei, scattered throughout
the cytoplasm [2]. The late stages, are characterized by the
presence of a variable number of apoptotic bodies which
undergo secondary necrosis or phagocytosis by neighboring
cells [3,4]. The destruction of the structural organization of
chromatin is secondary to DNA cleavage [5] and proteolysis
of nuclear components which, in turn, are responsible for
nuclear destabilization.
A number of nuclear membrane and nuclear lamina [6]
components have been implicated in the apoptotic process,
including lamina associated polypeptide 2L (LAP2L) [7] and
K (LAP2K) [8], lamin B receptor (LBR) [9] and proteins of the
nuclear pore complex [7,9]. Lamins [6,10,11], poly(ADP-ri-
bose)polymerase (PARP) [12^14], topoisomerase I and II
and a number of constitutive transcription factors [15] are
also cleaved in apoptotic nuclei.
Emerin is a serine-rich nuclear membrane-anchored protein
which shows a sequence similarity with LAP2 and MAN1
[16,17]. The protein is linked to the nuclear lamina [18] and
interacts with lamin A/C [19^21]. Emerin functional interac-
tion with lamin A/C has been demonstrated: (1) during mi-
tosis, emerin is redistributed in the cytoplasm following the
fate of lamins [22,23] ; emerin and lamin A/C colocalize at the
nuclear envelope, but do not colocalize after mitotic nuclear
membrane breakdown [22] ; (2) embryonic ¢broblasts ob-
tained from mice null for the lamin A/C gene show a displace-
ment of emerin from the nuclear envelope and a relocalization
of this protein to the cytoplasm [20]; (3) mutations in emerin
or lamin A/C genes cause the same disease, the Emery^Drei-
fuss muscular dystrophy (EDMD) [24,25]. The clinical symp-
toms of EDMD are early contractures, muscle weakness and
wasting and cardiomyopathic defects [26]. In most X-linked
EDMD a¡ected patients, emerin is absent from the nuclear
membrane of any cell type.
While it is well known that lamin A/C is cleaved by caspase
6 during programmed cell death [6], the behavior of emerin in
apoptotic nuclei has only been described in Jurkat T cells
following anti-Fas antibody treatment [8]. In this experimental
model emerin is not processed during apoptosis and the au-
thors suggest a role for emerin in maintaining chromatin as-
sociation with the nuclear envelope in apoptotic lymphoblas-
toid cells [8]. Since muscle is the a¡ected tissue in the EDMD,
it appears of great interest to investigate emerin fate during
myoblast apoptosis. Previously, it has been reported that
emerin expression is related to myogenic di¡erentiation of
cultured myoblasts [27], suggesting a role for this ubiquitous
protein in the turn-over of muscle tissue. Programmed cell
death occurs during in vitro myogenesis [28] and during em-
bryonic muscle development [29] ; indeed, myoblasts undergo
programmed cell death during normal proliferation and di¡er-
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entiation, but after fusion, myotubes acquire resistance to ap-
optosis [30^32].
In this study, we analyzed emerin fate in proliferating
mouse myoblasts and di¡erentiating myotubes during the ap-
optotic breakdown of the nucleus. Induction of apoptosis by
two di¡erent protocols allowed us to show that emerin pro-
teolysis occurs in apoptotic myoblast nuclei and it is related to
activation of caspase 6, the protease involved in lamin A/C
cleavage.
2. Materials and methods
2.1. Cell culture
Mouse C2C12 myoblasts were cultured in Dulbecco’s modi¢ed Ea-
gle’s medium (DMEM) supplemented with 15% fetal calf serum (FCS,
Gibco BRL Life Technologies, Paisley, UK). As the cells approached
con£uence, the growth medium was replaced with di¡erentiation me-
dium (DMEM plus 2% horse serum) to obtain multinucleated myo-
tubes. Apoptosis was induced by serum deprivation of the culture [31]
for 24, 48 or 72 h or by treatment with 1 WM staurosporine [28]; both
exponentially growing myoblasts and myotubes at day 5 of di¡eren-
tiation were treated and harvested as £oating cells. Cells were in part
employed for the biochemical analysis, while an aliquot of cells was
used for DNA extraction and agarose gel electrophoresis. Laminin-
coated slides were used to culture myoblasts to be analyzed by
immunocytochemistry.
2.2. Incubation of cultures with caspase inhibitors
Caspase 3 inhibitor Ac-Asp-Glu-Val-L-aspartic acid aldehyde (Ac-
DEVD-CHO) and caspase 6 inhibitor Ac-Val-Glu-Ile-aspartic acid
aldheyde (Ac-VEID-CHO) were purchased from Calbiochem (La Jol-
la, CA, USA). Each inhibitor was added to myoblast cultures 2 h
before staurosporine administration and treatment was applied for
additional 8 h. Both inhibitors were used at 50 and 100 WM concen-
tration [7].
2.3. DNA ladder analysis
Total DNA was puri¢ed from cell pellets obtained from either
control or treated myoblasts after staurosporine administration or
serum starvation for the speci¢ed time. A DNA extraction kit (Qia-
gen, Italy) was used according to the manufacturer’s protocol and
DNA concentration was determined by measuring the absorbance
at 260 nm. Aliquots of 5 Wg of DNA in TE bu¡er (0.1 M Tris^
HCl, pH 8.0, 10 mM EDTA) were loaded for each sample on 2%
agarose gel, subjected to electrophoresis at a constant current of 20 V,
visualized with ethidium bromide (0.4 Wg/ml) by a UV transillumina-
tor (302 nm) and the gel was photographed with a Polaroid camera.
2.4. Immunoblotting
Myoblasts and myotubes were lysed in a bu¡er containing Tris^
HCl pH 7.4, 1% Nonidet P-40, 10 mM 2-mercaptoethanol, and
protease inhibitors (leupeptin 2 Wg/ml, aprotinin 2 Wg/ml, PMSF
1 mM). Aliquots corresponding to 90 Wg proteins were subjected to
15% SDS^PAGE, transferred onto a nitrocellulose membrane and
Western blotted with the speci¢ed antibodies. All antibodies were
diluted in phosphate-bu¡ered saline (PBS)^Tween 20 at the following
dilutions: anti-emerin, monoclonal (Novocastra, UK), 1:250; anti-
emerin (C-terminus), polyclonal (Santa Cruz, CA, USA), 1:100;
anti-emerin polyclonal [33], 1:500; anti-lamin A/C, polyclonal (Santa
Cruz), 1:1500; anti-PARP, polyclonal (Cell Signaling Technologies,
MA, USA), 1:300. Secondary antibodies were diluted as suggested by
the manufacturer. Experiments were run on three di¡erent cultures for
each point. Immunoblotted bands were visualized by enhanced chem-
iluminescence (Amersham International, UK).
2.5. Immunocytochemistry
Expression of emerin was evaluated in myoblast cultures treated
with staurosporine for 8 h, using monoclonal anti-emerin antibody.
Lamin A/C distribution was detected by a polyclonal antibody. Fixed
cells were permeabilized with 0.15% Triton X-100 and incubated in
PBS^4% bovine serum albumin pH 7.4 to block non-speci¢c binding.
Primary antibodies were incubated at 4‡C overnight, while secondary
antibodies were used at room temperature for 30^60 min. The follow-
ing dilutions were employed: anti-emerin, monoclonal, 1:20; anti-
lamin A/C, 1:100; anti-mouse IgG Cy3-conjugated (Sigma, MO,
USA), 1:10 000 and anti-goat IgG £uorescein isothiocyanate-conju-
gated (Dako), 1:100. Slides were counterstained with 4,6-diamidino-
2-phenylindole (DAPI, 0.1 Wg/ml) (Sigma). Control slides were per-
formed in the absence of the primary antibodies.
2.6. Electron microscopy
Cell pellets from control myoblasts and from 18 h staurosporine-
treated myoblasts were ¢xed with 2.5% glutaraldehyde 30.1 M phos-
phate bu¡er pH 7.6 for 1 h at room temperature. After post-¢xation
with 1% OsO4 in veronal bu¡er for 1 h, pellets were dehydrated in an
ethanol series and embedded in Epon resin. Formvar carbon-coated
grids were used as thin sections support. Thin sections stained with
uranyl acetate and lead citrate were observed with a Philips EM 400
transmission electron microscope.
2.7. DNA breaks detection by in situ end-labeling and
cell viability analysis
The percentage of apoptotic nuclei in myoblast cultures transfected
with the full-length emerin cDNA or with the empty vector was eval-
uated after staurosporine treatment. To label apoptotic nuclei, the 3P-
OH end of DNA fragments were visualized by the method of terminal
transferase-mediated dUTP nick end-labeling (TUNEL) using the Ap-
optosis Detection System £uorescence kit (Promega, WI, USA) ac-
cording to the manufacturer’s instructions.
3. Results
Emerin expression and proteolysis were studied in apoptotic
nuclei of C2C12 myoblasts and myotubes. Both staurosporine
treatment and serum starvation of cultures were e¡ective in
inducing myoblast apoptosis as shown by the analysis of lam-
in A/C and PARP cleavage.
3.1. Kinetics of emerin proteolysis
The time-course of emerin expression in C2C12 apoptotic
myoblasts is reported in Fig. 1; staurosporine-treated myo-
blasts showed the same kinetics of emerin proteolysis as ob-
served for the serum deprivation alone, but with a faster time-
course. Emerin proteolysis was detectable in staurosporine-
treated myoblasts (Fig. 1A) at the time-point 4 h. In serum-
starved cells (Fig. 1B) the proteolysis of emerin started within
24 h of apoptosis induction. The emerin 34 kDa band was
strongly reduced at 18 h of staurosporine treatment as well as
at 72 h of serum starvation. After 30 h of staurosporine treat-
ment or 96 h of serum starvation emerin was hardly detect-
able by Western blot analysis, possibly because secondary
degradation of protein occurred at these late stages of the
apoptotic process.
A cleavage peptide of about 20 kDa was detected in all the
apoptotic samples by Western blot analysis performed with a
polyclonal antibody raised against the C-terminus of mouse
emerin. At the time-point 18 h the native 34 kDa band was
hardly detectable in staurosporine-treated myoblasts, while
the low molecular weight fragment was sharply labeled.
Cells still adherent to the plastic substrate at any time-
point, and after induction of apoptosis using either experi-
mental protocol, showed a slightly reduced emerin band of
34 kDa, as expected for pre-apoptotic cells (not shown) [28].
3.2. Emerin fate in apoptotic myotubes
Emerin proteolysis was also studied in apoptotic myotubes
(Fig. 2A); staurosporine treatment or 48 h serum deprivation
were e¡ective in inducing a strong reduction of emerin
amount in di¡erentiated cells. To rule out the possibility
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that C2C12 myotubes treated with staurosporine were ne-
crotic, a control sample performed by treatment with 10%
ethanol [7] was loaded in the polyacrylamide gel; the emerin
amount was not lowered in this sample (Fig. 2A, lane N).
Lamin A/C and PARP cleavage were analyzed in the same
samples (Fig. 2B) to show induction of apoptosis. A precise
correspondence was observed between emerin proteolysis and
lamin A/C cleavage; lamin A/C cleavage was an early event,
as low molecular weight peptides (about 37 kDa) appeared
even at the early time-points of staurosporine treatment
Fig. 1. Time-course of emerin proteolysis in C2C12 myoblasts. C2C12 myoblasts were incubated with staurosporine (A,C) or serum-starved for
the speci¢ed time-points (B,D). Whole cell extracts were analyzed by SDS^PAGE. 90 Wg of proteins were loaded in each lane and immunoblots
were revealed using goat polyclonal anti-emerin. The 20 kDa band represents the cleaved emerin fragment. C,D: The densitometric analysis of
the 34 kDa immunoblotted bands shown in (A,B), respectively; values are reported in arbitrary units as percentage of controls (time-point 0).
The same pattern of proteolysis is maintained, despite the di¡erent experimental conditions. The rate of apoptotic cells per each time-point,
evaluated by DAPI staining of nuclei, is reported in parentheses.
Fig. 2. Emerin proteolysis in C2C12 myotubes treated with staurosporine for 18 h or serum-starved (3FCS) for 72 h. A: Immunoblotted bands
were obtained after SDS^PAGE of whole cell extracts and detection by anti-emerin polyclonal antibody. Note that emerin proteolysis does not
occur in necrotic ethanol-treated cells (N). B: Lamin A/C cleavage was observed in the same samples, and native lamin A/C bands disappeared
in apoptotic samples, while emerin proteolysis was not complete at the same time-points (18 h of staurosporine treatment and 72 h of serum
starvation). Anti-lamin A/C polyclonal antibody was employed to reveal immunoblotted bands. C: PARP cleavage was analyzed in the same
samples. The 85 kDa active enzyme is detectable in apoptotic myotubes, while the 110 kDa pro-enzyme is faintly labeled by the antibody em-
ployed and it is only represented in control untreated and necrotic cells. Molecular weight markers are reported on the right. D: The DNA
ladder of apoptotic nuclei is shown. DNA fragmentation is evident at 18 h of staurosporine treatment or 72 h of serum starvation. Molecular
size markers are expressed as number of base pairs.
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(Fig. 2B). In myotubes treated with staurosporine for 18 h
native lamin A/C band almost disappeared (Fig. 2B); this ¢nd-
ing was consistent with the strong reduction of the 34 kDa
emerin band observed in the same samples (Fig. 2A). Cleaved
PARP was detected at any time-point of staurosporine treat-
ment and in serum-starved myotubes, while only the 110 kDa
inactive enzyme was observed in control and ethanol-treated
cells (Fig. 2C). Fig. 2D shows the DNA ladder analysis of
apoptotic myotubes. Oligonucleosomal DNA cleavage was ob-
served after 18 h of staurosporine treatment or after 72 h of
serum starvation of cultures.
3.3. Immunocytochemistry
Both staurosporine-treated and serum-starved cells were re-
acted with anti-emerin monoclonal antibody and anti-lamin
A/C polyclonal antibody to evaluate the intensity of labeling
and the localization of emerin in apoptotic myoblasts and
myotubes. Fig. 3 shows double-labeled myoblasts after 8 h
staurosporine treatment. A reduction of emerin-labeling
(Fig. 3D) and of lamin A/C staining (Fig. 3E) was clearly
evident in the cells with condensed chromatin (Fig. 3F), typ-
ical of apoptotic nuclei. The same decrease of emerin staining
was observed in myotubes (not shown).
3.4. Electron microscopy
Electron microscopy analysis of apoptotic C2C12 nuclei
showed a similar morphology both in myoblasts and myo-
tubes. Fig. 4A shows the morphology of a myoblast nucleus
from a di¡erentiating C2C12 culture. In staurosporine-treated
cells chromatin was compacted along the nuclear periphery
(Fig. 4B), while the nuclear lamina was still preserved. On
the other hand, mitochondria were altered and the cytoplasm
was condensed, while the plasma membrane was still intact
(Fig. 4B). The nuclear membrane appeared intact with nuclear
pores more evident in regions where the compacted chromatin
was absent. However, condensed chromatin was not closely
attached to the nuclear lamina, as shown in Fig. 4C.
3.5. Role of caspases in emerin proteolysis
We evaluated the involvement of caspase 3 and caspase 6 in
the proteolysis of emerin observed during the apoptotic pro-
cess. As expected, caspase 3 inhibitor Ac-DEVD-CHO and
caspase 6 inhibitor Ac-VEID-CHO, employed at 100 WM con-
centration in C2C12 myoblasts, inhibited PARP and lamin
A/C cleavage, respectively (Fig. 5). Emerin proteolysis was
completely abolished by both competitor substrates (Fig.
5A,B). Polyclonal anti-emerin antibody revealed a cleaved
peptide of 20 kDa in lysates obtained from apoptotic cells,
which was not labeled by the monoclonal antibody. This pep-
tide was absent in cell lysates where caspase inhibitors had
been added (Fig. 5B, lanes 3 and 4).
3.6. Emerin over-expression in staurosporine-treated myoblasts
Over-expression of wild-type emerin in cycling myoblasts
did not increase resistance of transfected cells to apoptosis.
The percentage of TUNEL positive nuclei within transfected
myoblasts was not statistically di¡erent from that observed in
controls (not shown).
Fig. 3. Emerin-labeling at the nuclear rim is strongly reduced in ap-
optotic nuclei. Control C2C12 myoblasts are shown in (A^C). Myo-
blasts treated with staurosporine for 8 h are shown in (D^F). Cells
¢xed with 2% paraformaldehyde were labeled with anti-emerin
monoclonal antibody (A,D) and anti-lamin A/C polyclonal antibody
(B,E). DAPI staining (C,F) allows detection of condensed and frag-
mented apoptotic nuclei indicated by arrows. Bar, 10 Wm.
Fig. 4. Electron microscopy analysis of the nuclear envelope in apoptotic C2C12 cells. A control nucleus is shown in (A). Myoblasts treated
with staurosporine for 18 h have a high degree of chromatin condensation (B). The detachment of the nuclear envelope from chromatin is
shown at higher magni¢cation in (C). n, nucleus; ne, nuclear envelope. Bars, 500 nm (A,B) and 10 nm (C).
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4. Discussion
In the present study we observed that: (1) cleavage of emer-
in occurs in apoptotic myoblasts and myotubes and gives rise
to a low molecular weight peptide of about 20 kDa; (2) emer-
in-labeling at the nuclear rim decreases upon the onset of
chromatin condensation and almost disappears at the late
stage of apoptosis; (3) inhibition of caspase 3 and caspase 6
activity completely abolishes emerin proteolysis in apoptotic
nuclei suggesting a direct involvement of caspase 6 in emerin
processing during apoptosis.
Involvement of nuclear envelope proteins, LAP2L [7], Nup
153 [7], LBR [9] and lamins [6] in the programmed cell death
has been demonstrated. The fate of emerin in apoptotic cells
was previously investigated in Jurkat lymphoid cells [8]. The
protein is not cleaved in this cellular model, suggesting that
emerin plays a role in maintaining the association of chroma-
tin with the nuclear envelope during the early stages of apo-
ptosis [8]. LBR, as well as emerin, was not proteolyzed in
human lymphoblastoid cells [7], but it was cleaved in apopto-
tic avian cells [9] and in human HeLa nuclei following mis-
targeting of lamin B and PP1 [34]. Using two di¡erent proto-
cols to induce apoptosis in C2C12 cells, we could detect
emerin proteolysis. Comparison of DNA ladder and emerin
Western blot analyses shows that complete emerin cleavage
occurs when DNA fragmentation is evident. Cleavage of lam-
in A/C in apoptotic myotubes appeared to follow a more
rapid kinetic than emerin processing, as shown in Fig. 2B.
In fact, complete proteolysis of native lamin A/C preceded
disappearance of the 34 kDa emerin band. This feature of
apoptotic nuclei suggests a role for emerin in maintaining
nuclear integrity until the late stages of programmed cell
death.
The immunoblotting analysis performed with anti-emerin
polyclonal antibody which is raised against the C-terminus
of murine emerin, shows that emerin cleavage in apoptotic
nuclei gives rise to one peptide of low molecular weight.
This fragment is not detected by the monoclonal anti-emerin
antibody, probably because the amino-terminal end of the
protein detected by this antibody is not contained in the
cleaved peptide.
In embryonic ¢broblasts obtained from mice null for the
lamin A/C gene, emerin is displaced from the nuclear rim and
it is redistributed in the cytoplasm [20]. This behavior would
have suggested a re-localization of emerin even in apoptotic
cells, where lamin A/C is cleaved. Our data concerning the
fate of emerin during programmed cell death, demonstrate
that the amount of emerin is strongly reduced in apoptotic
nuclei, but cytoplasmic staining is not increased. This feature
suggests that emerin processing in apoptotic nuclei is not only
dependent on lamin A/C cleavage.
Therefore, we investigated a possible involvement of cas-
pases [35^38] in emerin cleavage during programmed cell
death. The results reported here show that emerin proteolysis
is related to both caspase 3 and caspase 6 activity. Active
caspase 3 activates caspase 6 with a cascade pattern [38];
Fig. 5. E¡ect of caspase inhibitors on the in vivo proteolysis of emerin, PARP, and lamin A/C. A: C2C12 myoblasts were incubated for 2 h in
the presence of 100 WM Ac-DEVD-CHO (lane 3) and 100 WM Ac-VEID-CHO (lane 4), then in the presence of staurosporine for an additional
8 h. Control cells are shown in lane 1, apoptotic cells not treated with caspase inhibitors are shown in lane 2. Emerin proteolysis has been re-
vealed in this immunoblot by monoclonal anti-emerin antibody which fails to detect any cleavage peptide. Both caspase inhibitors completely
abolished emerin proteolysis. B: Emerin cleavage is detected, in the same samples shown in (A), by a polyclonal anti-emerin antibody raised
against the C-terminus of the mouse protein. A cleaved peptide of approximately 20 kDa is revealed. Both caspase 3 and caspase 6 inhibitors
strongly reduce the amount of cleaved peptide (lanes 3 and 4). C: PARP proteolysis is analyzed by an immunoblotting performed on the same
samples shown in (A,B); note that caspase 3 inhibitor strongly reduces PARP cleavage (lane 3). D: Lamin A/C cleavage is analyzed in the
same samples as in (A^C). The 37 kDa product of lamin A/C proteolysis is detected in apoptotic myoblasts (lane 2). Caspase 6 inhibitor Ac-
VEID-CHO completely abolishes lamin A/C proteolysis (lane 4). E: The densitometric analysis of immunoblotted bands (34 kDa) labeled with
anti-emerin monoclonal antibody and here reported in A was performed. Results are reported as percentage of control (non apoptotic cells)
densitometric value (1) and represent the values for apoptotic myoblasts (2), apoptotic myoblasts treated with Ac-DEVD-CHO (3) and apopto-
tic myoblasts treated with Ac-VEID-CHO (4). The values are representative of three di¡erent experiments.
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thus, inhibition of emerin cleavage by both competitor sub-
strates strongly suggests that caspase 6 is directly involved in
emerin cleavage. Nevertheless, caspase 6 is known to cleave
lamin A/C. Therefore, inhibition of emerin proteolysis by cas-
pase 6 substrate, suggests either a correlation between lamin
A/C cleavage and emerin processing in apoptotic nuclei or a
direct interaction of the protease with emerin. The binding site
of emerin on the lamin A/C sequence has been identi¢ed in
the tail domain of lamin A (amino acids 384^566) [39], while
the caspase 6 cleavage site corresponds to Asp230 in the lamin
A sequence [6]. Thus, the site of interaction between emerin
and lamin A is not a¡ected in caspase-cleaved lamin A, and
emerin binding should not be impaired. The identi¢cation of
caspase 6 as the emerin protease is supported by the presence
of consensus aspartic acid containing sequences [37,38] for
caspase 6 within the nucleoplasmic domain of emerin. Cleav-
age of emerin at V70DSD would generate a fragment of ap-
proximately 26 kDa, while cleavage at V126DAD would gen-
erate a fragment of about 19 kDa, which ¢ts with the
molecular weight of the observed proteolytic product. An
anti-emerin polyclonal antibody [33] raised against the N-ter-
minus of the protein allowed us to detect a fragment of 26
kDa in apoptotic myoblasts, which is absent from lysates
obtained after in vivo caspase 3 or caspase 6 blockage (not
shown). Thus, we cannot rule out the possibility that emerin is
cleaved at V70DSD. However, further studies, including mu-
tations within the possible caspase cleavage motifs, are needed
in order to characterize the in vivo cleavage site for caspase
6 in the emerin sequence. It is worth noting that emerin cleav-
age at one or more of the caspase 6 consensus sequences here
reported should a¡ect the emerin domain involved in lamin
A/C interaction (amino acids 1^188) [16,21,39]. Thus, emerin
proteolysis could facilitate the breakdown of the nuclear lam-
ina^nuclear matrix that occurs during programmed cell death
[40,41], provided that emerin is linked to these structures in
living cells [18]. Moreover, the detachment of nuclear envelope
from chromatin here observed in apoptotic nuclei (Fig. 4) has
been related to cleavage of inner nuclear membrane proteins
[41], and could also involve emerin proteolysis. It is tempting
to speculate that also processing of cytoplasmic structures in
apoptotic muscle cells could be facilitated by emerin proteol-
ysis; in fact, we previously reported an extra-nuclear local-
ization of the protein in di¡erentiating myoblasts [27] and
hypothesized an involvement of emerin in cytoskeleton orga-
nization; moreover, an impaired organization of egg cyto-
plasm in Drosophila due to mutations in a nuclear lamin
has been recently described [42].
Over-expression of wild type emerin in myoblasts did not
elicit a protective e¡ect against apoptosis induction; the sug-
gested absence of a survival role of emerin in myogenic cells,
is consistent with our results showing the same rate of pro-
grammed cell death in EDMD cells carrying a null mutation
in the emerin gene, as in control human cells (not shown).
This ¢nding also agrees with cleavage of emerin in apoptotic
muscle nuclei being a late event not involved in triggering of
the apoptotic nuclear mechanisms.
The results reported here describe the fate of emerin in
apoptotic myoblasts. It should be interesting to evaluate the
processing of the protein in other cell types undergoing
programmed cell death, to investigate whether the biological
mechanism here described is shared by di¡erent tissues or
it is a feature of myoblasts. In this respect, the absence of
emerin processing in lymphoid T cells undergoing pro-
grammed cell death [8] should support the latter hypothesis.
It is worth noting that an apoptosis repressor selectively ex-
pressed in myoblasts has been reported [43] and this could
suggest the existence of apoptotic pathways speci¢c for muscle
cells.
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